GoldenGolden
Advanced Search
DiCE Molecules

DiCE Molecules

Small molecule compounds that act by unlocking protein-protein interfaces

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

August 24, 2021
DiCE Molecules raises $60,000,000 in series C-1 financing, round led by RA Capital Management and Sands Capital, with participation from Janus Henderson Investors, Deep Track Capital, Logos Capital, Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management.
January 2021
DiCE Molecules raises a $80,000,000 series C round from Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, L.P., Driehaus Capital Management, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, RA Capital Management, Sands Capital Management, Sanofi Ventures and Soleus Capital Management.
January 2021
DiCE Molecules raises a $80,000,000 series C round from Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, L.P., Driehaus Capital Management Llc, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, RA Capital Management, Sands Capital Management, Sanofi Ventures and Soleus Capital Management.

Funding rounds

People

Further reading

Documentaries, videos and podcasts

Companies

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
August 26, 2021
FierceBiotech
DiCE Molecules raised $60 million in a series C extension on Tuesday. The next day, the eight-year-old preclinical biotech filed for an initial public offering to take its oral small-molecule therapeutics into the clinic.
FinSMEs
August 24, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amirah Al Idrus
January 8, 2021
FierceBiotech
DiCE Molecules is setting its sights on the clinic. With $80 million raised from a laundry list of investors led by RA Capital Management, the company will push its lead program, an interleukin-17 antagonist, into a clinical trial in psoriasis and build out its preclinical programs.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.